Profile data is unavailable for this security.
About the company
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated2000
- Employees4.00
- LocationEpigenomics AGGeneststrasse 5BERLIN 10829GermanyDEU
- Phone+49 30243450
- Fax+49 3 024345555
- Websitehttps://www.epigenomics.com/
Holder | Shares | % Held |
---|---|---|
FPS Verm�gensverwaltung GmbHas of 31 Dec 2023 | 29.00 | 0.02% |